Senseonics: Senseonics highlights early success with Eversense 365 launch

Senseonics (NYSE:SENS) today announced significant progress with the launch of its Eversense 365 continuous glucose monitor (CGM). In September, the company won FDA clearance for the Eversense 365 one-year implantable CGM. With the clearance, it became the world's first 365-day CGM system. Senseonics and its global distribution partner, Ascensia Diabetes Care, announced the launch for Eversense 365 [...]The post Senseonics highlights early success with Eversense 365 launch appeared first on Drug Delivery Business.